仕事
FDA adcomm votes in favor of Alnylam's new indication for Onpattro – Endpoints News
- FDA adcomm votes in favor of Alnylam’s new indication for Onpattro Endpoints News
- FDA panel endorses Alnylam’s heart drug — after picking apart its supporting data STAT
- Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Yahoo Finance
- U.S. FDA panel backs expanded use of Alnylam’s gene silencing drug AOL
- Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease FiercePharma
- View Full Coverage on Google News
Source link
